Not FDA-approved2Evidence: Smaller human trialsInflammation and immune

LL-371,2

Also called Cathelicidin LL-37, Ropocamptide, LL371

Key takeaway

LL-37 is a 37-amino-acid peptide of the human cathelicidin family, recorded in FDA’s substance registry as cathelicidin LL-37 (human), with the international name ropocamptide.1 It has been tested in small randomized trials in chronic leg and foot ulcers. The largest, in 148 people with venous leg ulcers, found no significant difference in healing compared with placebo.6,7,8 FDA lists cathelicidin LL-37 among compounding substances that may present significant safety risks, stating that it lacks enough safety information to know whether LL-37 would cause harm in people, and noting nonclinical findings of harm to male reproduction and tumor promotion.2 No FDA approval is reported in the sources reviewed here, and LL-37 is not among the six peptides in HHS’s October 2026 draft policy.2,4

LL-37 at a glance

What it isA 37-amino-acid peptide beginning with two leucines (hence LL-37), recorded as human cathelicidin LL-37 and ropocamptide in FDA’s substance registry.1
FDA statusNo FDA approval is reported in the sources reviewed here. FDA lists cathelicidin LL-37 among bulk substances whose compounding nominations were withdrawn and that may present significant safety risks.2
Human evidenceThree small randomized, placebo-controlled trials in chronic ulcers, with mixed results: two reported faster healing, and the largest found no significant difference overall.6,7,8
Evidence strengthSmaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned

What is LL-37?

LL-37 is a peptide of 37 amino acids, starting with two leucines, that FDA’s substance registry records as cathelicidin LL-37 (human) and under the international nonproprietary name ropocamptide.1

The company behind the venous leg ulcer trials states that it is developing LL-37 under the name ropocamptide.7

How is LL-37 thought to work?

The authors of the 2023 diabetic foot ulcer trial describe LL-37 as having antimicrobial properties and as promoting new blood vessel formation and the movement and growth of skin cells.8

Those are researchers’ descriptions of proposed actions. The FDA sources reviewed here do not describe how LL-37 works, and report nonclinical findings on its possible harms.2,8

What do human studies show?

In a 2014 first-in-human trial in 34 people with hard-to-heal venous leg ulcers, the two lower LL-37 strengths were reported to speed healing compared with placebo over four weeks, while the highest strength showed no difference. The authors reported no safety concerns.6

HEAL LL-37, a larger randomized, placebo-controlled trial in 148 people with venous leg ulcers published in 2021, did not find a significant difference in healing between LL-37 and placebo in the whole study population. An after-the-fact analysis suggested a benefit in people with large ulcers, which the authors say needs a properly powered trial.7

In a 2023 randomized, double-blind trial in 25 people with mildly infected diabetic foot ulcers, granulation, a measure of wound healing, increased more with LL-37 than with placebo, but inflammation markers and bacterial counts did not fall more.8

ClinicalTrials.gov also lists a study of LL37 in melanoma (NCT02225366), listed as Phase 1/Phase 2 and completed in its December 9, 2021 record. A registration lists what was planned; it does not show whether LL-37 worked.9

FDA states that it lacks sufficient safety-related information on cathelicidin LL-37 to know whether it would cause harm when given to humans.2

What the evidence base contains

  • Controlled human trial HEAL LL-37: a double-blind, randomized, placebo-controlled Phase 2b trial in 148 people with hard-to-heal venous leg ulcers, alongside compression therapy. It found no significant improvement in healing in the whole study population.7
  • Controlled human trial A first-in-human trial in 34 people with hard-to-heal venous leg ulcers, with a four-week randomized, double-blind comparison of three LL-37 strengths against placebo.6
  • Controlled human trial A randomized, double-blind trial in 25 people with mildly infected diabetic foot ulcers (13 given LL-37, 12 placebo) for four weeks.8
  • Animal or laboratory research Nonclinical research findings, cited by FDA, suggesting harmful effects on male reproduction and that LL-37 can promote tumor growth in some tissues.2

Evidence-strength label: Smaller controlled human trials. How this label is assigned

Is LL-37 FDA-approved?

None of the sources reviewed here reports an approval of LL-37 by FDA.1,2

FDA’s compounding safety-risk page, current as of April 22, 2026, lists cathelicidin LL-37 among bulk substances previously in category 2 whose nominations were withdrawn, citing possible immune reactions and characterization problems.2

FDA’s page for the next meeting of its Pharmacy Compounding Advisory Committee, current as of April 15, 2026, lists cathelicidin LL-37 among substances the committee will discuss for the 503A bulks list at a meeting before the end of February 2027, with the date not yet set.5

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. LL-37 is not among them.3,4

Timeline

  1. Results of a first-in-human randomized trial of LL-37 in venous leg ulcers are published.6
  2. Results of the HEAL LL-37 trial in venous leg ulcers are published, finding no significant difference from placebo overall.7
  3. Results of a randomized trial of LL-37 in diabetic foot ulcers are published.8
  4. FDA’s advisory committee page lists cathelicidin LL-37 for discussion at a meeting before the end of February 2027.5
  5. FDA’s compounding safety-risk page, as last updated, lists cathelicidin LL-37 among withdrawn nominations with safety concerns.2

What is still unknown?

Whether it helps ulcers heal: the largest trial reviewed here found no significant difference from placebo, and the others were small.6,7,8

Whether it is safe in people, which FDA states it lacks the information to judge, and whether the reproductive and tumor-promoting effects seen in nonclinical research apply to people.2

What FDA’s advisory committee will conclude; its page did not give a meeting date.5

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for LL-37: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for LL-37 are a bounded selection, not every registration or paper about LL-37. For the years before LL-37 was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list LL-37 as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name LL-37 in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

No FDA approval reported; on FDA’s compounding safety-risk list. Three small randomized trials in chronic leg and foot ulcers report mixed results; the largest found no significant difference from placebo. FDA states that it lacks sufficient safety information on LL-37 in people. LL-37 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗↗

Status sources checked through November 14, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of LL-37?

No FDA approval reported; on FDA’s compounding safety-risk list. Three small randomized trials in chronic leg and foot ulcers report mixed results; the largest found no significant difference from placebo. FDA states that it lacks sufficient safety information on LL-37 in people. LL-37 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗↗

The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
2
Source years
7
Drugs@FDA applications
0

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected regulatory records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to LL-37?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

31Selected dated records
39Connected citations
7Populated source years2020–2026
2/4Record lanes present

Registered human studies

Trial composition

1 of 1 selected trial records include at least one phase value; 1 of 1 include a status value in the retained structured contract.

PhasesPhase 1 1Phase 2 1
Status at observationCompleted 1

PubMed bibliography

Publication composition

30 of 30 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 30Review 28Research Support, N.I.H., Extramural 3Research Support, Non-U.S. Gov't 2Clinical Trial 1Comparative Study 1English Abstract 1Randomized Controlled Trial 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
0
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
31

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 31 dated records

Research hub

Explore the LL-37 evidence record

Open all 31 records →
31Dated records
2Evidence types
31Cited public sources
7Source years

Change ledger

Recently changed for LL-37

Open all 32 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Profile updated

LL-37 profile

We added three randomized trials of LL-37 in chronic ulcers, FDA’s advisory committee page listing LL-37 for a meeting before the end of February 2027, and the spelling LL37 that trial registrations use, so that those registrations are matched.

PeptideScanner change date
November 16, 2026
Evidence lane
Profile
Record added

ClinicalTrials.gov record NCT02225366

PeptideScanner retained ClinicalTrials.gov record NCT02225366 at 2026-11-16T16:10:17.145Z. Its registry update date was 2021-12-09, and PeptideScanner's reviewed identity mapping was ll-37.

PeptideScanner change date
November 16, 2026
Cited source date
December 9, 2021
Evidence lane
Clinical trials
Record added

Defensins and LL-37: a review of function in the gingival epithelium.

PubMed lists PMID 23931055 in Periodontology 2000 as Journal Article, Research Support, N.I.H., Extramural, Review, with publication-date metadata of 2013-10 (month precision). PeptideScanner associated the retained record with the identity slug ll-37. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
May 15, 2024
Evidence lane
Literature metadata

Official-source collections

Source records for LL-37

Open the full research atlas →
PubMed30

30 with attributed title, venue, publication-date, and type metadata.

  1. LL-37-MRGPRX2-Mast Cell Signaling in Rosacea: Current Evidence and Directions for Human Studies.Clinical, cosmetic and investigational dermatology · 2026 10 07
  2. LL-37: Biological Mechanisms and Emerging Therapeutic Applications in Intestinal Disease.Immunity, inflammation and disease · 2026 May
  3. Decoding LL-37: Structure and antimicrobial mechanisms against microbial threats.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2025 11 19
Explore all selected literature →

Evidence types

Coverage by source year

Selected records span September 28, 2020 to October 31, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. Food and Drug Administration1,2
  • U.S. Department of Health and Human Services3
Dated updates connected to this profile · 31

Updates connected to this profile

Open the full cross-source timeline →
  1. Literature metadata

    Antifungal properties of cathelicidin LL-37: current knowledge and future research directions.↗

    PubMed lists PMID 38057654 in World journal of microbiology & biotechnology as Journal Article, Review, with publication-date metadata of 2023-12-07 (day precision). PeptideScanner associated the retained record with the identity slug ll-37. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Antibiofilm properties of cathelicidin LL-37: an in-depth review.↗

    PubMed lists PMID 36781570 in World journal of microbiology & biotechnology as Review, Journal Article, with publication-date metadata of 2023-02-14 (day precision). PeptideScanner associated the retained record with the identity slug ll-37. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    LL-37-MRGPRX2-Mast Cell Signaling in Rosacea: Current Evidence and Directions for Human Studies.↗

    PubMed lists PMID 42861262 in Clinical, cosmetic and investigational dermatology as Journal Article, Review, with publication-date metadata of 2026-10-07 (day precision). PeptideScanner associated the retained record with the identity slug ll-37. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    LL-37: Biological Mechanisms and Emerging Therapeutic Applications in Intestinal Disease.↗

    PubMed lists PMID 42095322 in Immunity, inflammation and disease as Journal Article, Review, with publication-date metadata of 2026-05 (month precision). PeptideScanner associated the retained record with the identity slug ll-37. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    LL-37: Structures, Antimicrobial Activity, and Influence on Amyloid-Related Diseases.↗

    PubMed lists PMID 38540740 in Biomolecules as Journal Article, Review, Research Support, N.I.H., Extramural, with publication-date metadata of 2024-03-08 (day precision). PeptideScanner associated the retained record with the identity slug ll-37. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Literature metadata

    Between good and evil: Complexation of the human cathelicidin LL-37 with nucleic acids.↗

    PubMed lists PMID 37919905 in Biophysical journal as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-11-02 (day precision). PeptideScanner associated the retained record with the identity slug ll-37. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Literature metadata

    Decoding LL-37: Structure and antimicrobial mechanisms against microbial threats.↗

    PubMed lists PMID 41270816 in Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases as Journal Article, Review, with publication-date metadata of 2025-11-19 (day precision). PeptideScanner associated the retained record with the identity slug ll-37. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Literature metadata

    Significance of the LL-37 Peptide Delivered from Human Cathelicidin in the Pathogenesis, Treatment, and Diagnosis of Sepsis.↗

    PubMed lists PMID 40960088 in Archivum immunologiae et therapiae experimentalis as Journal Article, Review, with publication-date metadata of 2025-09-07 (day precision). PeptideScanner associated the retained record with the identity slug ll-37. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Literature metadata

    Antimicrobial Peptides of the Cathelicidin Family: Focus on LL-37 and Its Modifications.↗

    PubMed lists PMID 40869425 in International journal of molecular sciences as Journal Article, Review, with publication-date metadata of 2025-08-21 (day precision). PeptideScanner associated the retained record with the identity slug ll-37. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  10. Literature metadata

    Cathelicidin LL-37 in periodontitis: current research advances and future prospects - A review.↗

    PubMed lists PMID 39954662 in International immunopharmacology as Journal Article, Review, with publication-date metadata of 2025-02-15 (day precision). PeptideScanner associated the retained record with the identity slug ll-37. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  11. Literature metadata

    Cathelicidin peptide LL-37: A multifunctional peptide involved in heart disease.↗

    PubMed lists PMID 39615616 in Pharmacological research as Journal Article, Review, with publication-date metadata of 2024-11-28 (day precision). PeptideScanner associated the retained record with the identity slug ll-37. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  12. Literature metadata

    LL-37, the master antimicrobial peptide, its multifaceted role from combating infections to cancer immunity.↗

    PubMed lists PMID 39643165 in International journal of antimicrobial agents as Journal Article, Review, with publication-date metadata of 2024-12-04 (day precision). PeptideScanner associated the retained record with the identity slug ll-37. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Ropocamptide (cathelicidin LL-37, human) substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  2. 2
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  3. 3
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  4. 4
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  5. 5
    Meeting of the Pharmacy Compounding Advisory Committee (before the end of February 2027) · content current as of April 15, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026

  6. 6
    Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial (2014) · PMID 25041740 ↗

    Wound Repair and Regeneration · Official source · Source checked November 16, 2026

  7. 7
    Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial (2021) · PMID 34687253 ↗

    Wound Repair and Regeneration · Official source · Source checked November 16, 2026

  8. 8
    Efficacy of LL-37 cream in enhancing healing of diabetic foot ulcer: a randomized double-blind controlled trial (2023) · PMID 37480520 ↗

    Archives of Dermatological Research · Official source · Source checked November 16, 2026

  9. 9
    ClinicalTrials.gov record NCT02225366 · retained source version 2021-12-09:d146b413ecf538257bf7086de94ac2024ae7cdada6f1e2c17c5051fba93f7d5c ↗

    ClinicalTrials.gov · Official source · Source checked November 16, 2026